-
Integrated Blood Pressure Control
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Evidence-based approach for managing hypertension in type 2 diabetes
Review
(3963) Views (876) Full article downloads
Authors: Gerti Tashko, Robert A Gabbay
Published Date May 2010
Volume 2010:3 Pages 31 - 43
DOI: http://dx.doi.org/10.2147/IBPC.S6984
Gerti Tashko1, Robert A Gabbay2
1Division of Endocrinology, Diabetes, and Metabolism, Penn State College of Medicine, Hershey, PA, USA; 2Penn State Institute for Diabetes and Obesity, Penn State College of Medicine, Penn State Milton S Hershey Medical Center, Hershey, PA, USA
Abstract: Blood pressure (BP) control is a critical part of managing patients with type 2 diabetes. Perhaps it is the single most important aspect of diabetes care, which unlike hyperglycemia and dyslipidemia can reduce both micro- and macrovascular complications. Hypertension is more prevalent in individuals with diabetes than general population, and in most cases its treatment requires two or more pharmacological agents (about 30% of individuals with diabetes need 3 or more medications to control BP). In this article we describe the key evidence that has contributed to our understanding that reduced BP translates into positive micro- and macrovascular outcomes. We review the data supporting current recommendation for BP target < 130/80 mmHg. Two studies suggest that a lower BP goal could be even more beneficial. We also present the comparative benefits of various antihypertensive drugs in reducing diabetes-related micro- and macrovascular complications. Finally we propose an evidence-based algorithm of how to initiate and titrate antihypertensive pharmacotherapy in affected individuals. Overall, achieving BP < 130/80 mmHg is more important than searching for the “best” antihypertensive agent in patients with diabetes.
Keywords: blood pressure control, treatment protocol, fixed dose combination, clinical inertia, adherence
Readers of this article also read:
Antihypertensive effects of astaxanthin
Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension
Clinical approach in treatment of resistant hypertension
De-stiffening drug therapy and blood pressure control
Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination
Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction
Critical appraisal of the differential effects of antihypertensive agents on arterial stiffness
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
Long-term use and tolerability of irbesartan for control of hypertension
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- The western diet and lifestyle and diseases of civilization
- Stiffness of the large arteries in individuals with and without Down syndrome
- Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study
- Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review




